ATR

Aptargroup Inc

Add to Watchlist

Advanced Chart

138.260

-0.46(-0.332%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

139.480

Open

138.890

VWAP

138.68

Vol

153.06K

Mkt Cap

9.14B

Low

138.110

Amount

21.23M

EV/EBITDA(TTM)

12.66

Total Shares

66.26M

10.07B

EV/OCF(TTM)

16.35

P/S(TTM)

2.60

AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

959.45M

+8.13%

1.420

+18.33%

905.80M

+6.81%

1.432

-5.81%

951.32M

+4.62%

1.570

+5.37%

Estimates Revision

The market is revising Downward the revenue expectations for AptarGroup, Inc. (ATR) for FY2025, with the revenue forecasts being adjusted by -0.33% over the past three months. During the same period, the stock price has changed by -12.54%.

Revenue Estimates for FY2025

Revise Downward

-0.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.57%

In Past 3 Month

Stock Price

Go Down

-12.54%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 167.33 USD with a low forecast of 153.00 USD and a high forecast of 177.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 138.260

Low

153.00

Averages

167.33

High

177.00

Current: 138.260

Low

153.00

Averages

167.33

High

177.00

Wells Fargo

Gabe Hajde

Overweight

downgrade

$173 -> $153

2025-08-04

Reason

Wells Fargo

Gabe Hajde

Price Target

$173 -> $153

2025-08-04

downgrade

Overweight

Reason

Wells Fargo analyst Gabe Hajde lowered the firm's price target on AptarGroup to $153 from $173 and keeps an Overweight rating on the shares. The firm notes Q2 results were strong, though driving shares lower Friday were the Q3 guide, litigation cost headwinds and normalizing growth of a key pharma product. With these items now looking priced in, next catalyst is the September Investor Day, Wells adds.

Raymond James

Matt Roberts

Outperform

downgrade

$182 -> $172

2025-08-04

Reason

Raymond James

Matt Roberts

Price Target

$182 -> $172

2025-08-04

downgrade

Outperform

Reason

Raymond James analyst Matt Roberts lowered the firm's price target on AptarGroup to $172 from $182 and keeps an Outperform rating on the shares. Aptar's defensible moats and fortress balance sheet, coupled with a specialty and growing position in Pharma end markets, make it a high-quality compounder story long-term, the analyst tells investors in a research note. The firm expects Pharma core sales to decelerate in Q3 and continues to expect Pharma core sales in 2025 to be below the 7%-11% long term target, but says that an improving mix and continued benefit from royalty revenue continues to drive strong margin performance, and the prior build-out of Injectables capacity is showing strong returns in higher margin Injectables components.

Wells Fargo

Overweight

maintain

$170 -> $173

2025-07-18

Reason

Wells Fargo

Price Target

$170 -> $173

2025-07-18

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on AptarGroup to $173 from $170 and keeps an Overweight rating on the shares. The firm notes that while calendar Q2 started with high uncertainty for the Packaging & Containers industry, results tracked largely in line with expectations, with FX a boost to those exposed. Beverage cans are likely strongest performers, while "value seeking behavior" a key headwind, Wells adds.

Raymond James

Outperform

maintain

$175 -> $182

2025-07-15

Reason

Raymond James

Price Target

$175 -> $182

2025-07-15

maintain

Outperform

Reason

Raymond James raised the firm's price target on AptarGroup to $182 from $175 and keeps an Outperform rating on the shares. Sentiment on Packaging names under coverage into their earnings reports remains tepid with the group underperforming the S&P 500 to date, the analyst tells investors in a research note. The firm expects Q2 reports to be broadly in line and 2025 guidance intact, albeit "shades" of caution for the second half of 2025.

Raymond James

Matt Roberts

Buy

Maintains

$190 → $175

2025-04-22

Reason

Raymond James

Matt Roberts

Price Target

$190 → $175

2025-04-22

Maintains

Buy

Reason

Raymond James lowered the firm's price target on AptarGroup to $175 from $190 and keeps an Outperform rating on the shares. The firm revised estimates for Packaging companies under coverage ahead of earnings with its estimate updates generally taking a more conservative volume approach as consumer trends starting in Q2 have sounded lackluster at best, the analyst tells investors in a research note. Based on the firm's stress test, Raymond James sees ~10%-20% downside to EPS estimates in a recession scenario.

Baird

Ghansham Panjabi

Buy

Maintains

$185 → $160

2025-02-10

Reason

Baird

Ghansham Panjabi

Price Target

$185 → $160

2025-02-10

Maintains

Buy

Reason

Baird analyst Ghansham Panjabi lowered the firm's price target on AptarGroup to $160 from $185 and keeps an Outperform rating on the shares. The firm said they see near-term headwinds but the long sterm story remains intact.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aptargroup Inc (ATR.N) is 22.83, compared to its 5-year average forward P/E of 28.23. For a more detailed relative valuation and DCF analysis to assess Aptargroup Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

28.23

Current PE

22.83

Overvalued PE

31.87

Undervalued PE

24.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

13.63

Current EV/EBITDA

12.04

Overvalued EV/EBITDA

14.86

Undervalued EV/EBITDA

12.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.48

Current PS

2.38

Overvalued PS

2.79

Undervalued PS

2.17